A multicenter experience with infliximab for ulcerative colitis: Outcomes and predictors of response, optimization, colectomy, and hospitalization

American Journal of Gastroenterology

Volumn 105, Issue 12, 2010, Pages 2617-2625

  Oussalah, Abderrahim ^a   Evesque, Ludovic ^b   Laharie, David ^c   Roblin, Xavier ^d   Boschetti, Gilles ^e   Nancey, Stéphane ^e   Filippi, Jérme ^b   Flourié, Bernard ^e   Hebuterne, Xavier ^b   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; HEMOGLOBIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; COLITIS; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMAN; JOINT CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCAPULAR CARCINOMA; SURGICAL RISK; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; FRANCE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78649893669     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.345     Document Type: Article

References (28)

1. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-76.
2. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infl iximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25: 19-37.
3. Ferrante M, Vermeire S, Fidder H et al. Long-term outcome aft er infl iximab for refractory ulcerative colitis. J Crohn's Colitis 2008;2: 219-25.
4. Su C, Salzberg BA, Lewis JD et al. Effi cacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97: 2577-84.
5. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early response to infl iximab in patients with ulcerative colitis. Infl amm Bowel Dis 2007;13: 123-8.
6. Gonzalez-Lama Y. P028 open-label infl iximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. J Crohn's Colitis Suppl 2007;1: 11.
7. Barreiro M, Lorenzo A, Mera J et al. W1262 prospective, open pilot study for evaluating the clinical effi cacy and mucosal healing rate of infl iximab in steroid-dependent ulcerative colitis. Gastroenterology 2008;134: A-667.
8. Sandborn WJ, Rutgeerts PJ, Feagan B et al. T1139 The ACT Trials: incremental benefi t of second and third induction doses of infl iximab in patients with moderately-to-severely active ulcerative colitis (UC). Gastroenterology 2008;134: A-492.
9. Arijs I, Li K, Toedter G et al. Mucosal gene signatures to predict response to infl iximab in patients with ulcerative colitis. Gut 2009;58: 1612-9.
10. Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infl iximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105: 1811-9.
11. Barreiro M, Lorenzo A, Dominguez-Munoz E. W1121 clinical effi cacy and mucosal healing rate of infl iximab in steroid-dependent ulcerative colitis: a prospective long-term follow-up study. Gastroenterology 2009;136: A-658.
12. Ferrante M, Vermeire S, Noman M et al. P088 colectomy rates aft er infl iximab for refractory ulcerative colitis and predictive factors. J Crohn's Colitis Suppl 2007;1: 26.
13. Jakobovits SL, Jewell DP, Travis SP. Infl iximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007;25: 1055-60.
14. Kohn A, Daperno M, Armuzzi A et al. Infl iximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26: 747-56.
15. Lees CW, Heys D, Ho GT et al. A retrospective analysis of the effi cacy and safety of infl iximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26: 411-9.
16. Seow CH, Newman A, Irwin SP et al. Trough serum infl iximab: a predictive factor of clinical outcome for infl iximab treatment in acute ulcerative colitis. Gut 2010;59: 49-54.
17. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison aft er treatment of ulcerative colitis with placebo or infl iximab. Gastroenterology 2009;137: 1250-60.
18. Stange EF, Travis SPL, Vermeire S et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: defi nitions and diagnosis. J Crohn's Colitis 2008;2: 1-23.
19. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classifi cation of infl ammatory bowel disease: controversies, consensus, and implications. Gut 2006;55: 749-53.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44: 837-45.
21. Sahai H, Khurshid A. Statistics in Epidemiology: Methods, Techniques, and Applications. CRC Press: Boca Raton, 1996.
22. Truelove SC, Witts LJ. Cortisone in ulcerative colitis;fi nal report on a therapeutic trial. Br Med J 1955;2: 1041-8.
23. Armuzzi A, De Vincentis F, Marzo M et al. W1143 long-term scheduled therapy with infl iximab in infl ammatory bowel disease. Gastroenterology 2009;136: A-663.
24. Oussalah A, Danese S, Peyrin-Biroulet L. Effi cacy of TNF antagonists beyond one year in adult and pediatric infl ammatory bowel diseases: a systematic review. Curr Drug Targets 2009;11: 156-75.
25. Arts J, D'Haens G, Zeegers M et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Infl amm Bowel Dis 2004;10: 73-8.
26. Sood A, Midha V, Sood N et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analysis of 24 cases. Indian J Gastroenterol 2008;27: 232-5.
27. Moskovitz DN, Van Assche G, Maenhout B et al. Incidence of colectomy during long-term follow-up aft er cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4: 760-5.
28. Actis GC, Lagget M, Rizzetto M et al. Long-term effi cacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med 2004;95: 65-70.